glp 1 oral drugs Structure Therapeutics GLP-1 Obesity Drug Achieves 'Injectable-Like Efficacy' in Phase 2 Test The GLP-1 Revolution: From Diabetes

5) Works in synergy with Glutathione

What we know about extended use The longest controlled human trials ran for 12 weeks

Kicking off 2026: Sparked by the long-awaited rise of non-opioid treatments, the first-ever - will capitalize on Vertex's recent success to transform efficacy and tolerability of pain management with Nav 1.8 & beyond: With rising anticipation for new targets like tau and LRRK2, the & returns as your flagship end-to-end forum for building on anti-amyloid approvals and strengthening biomarker assessments to reinvigorate the neurodegenerative treatment landscape: Concentrating on earlier-stage innovation, will unite those dedicated to translating discoveries of glial biology and peripheral immune pathways into novel approaches to target neuroinflammation across the neurodegenerative disease spectrum: Full details of the 2026 event schedule can be found in your copy of the World CNS 2026 Prospectus below

Haematopoietic stem cell transplantation for sickle cell disease current practice and new approaches

Carnitine supplementation has been found to have positive effects in improving these issues

This ensures consistency and reliability of experimental results in various research models